The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
31
No.
16
April 22, 2005
- SWOG, NCI Canada halt two large trials of Iressa for non-small cell lung cancer.
- Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products.
- National Cancer Policy Board calls for public-private partnership for R&D in pediatric cancer drugs.
- Paulette Gray named director of NCI Division of Extramural Activities.
CCL
Vol.
28
No.
4
April 29, 2005
- NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit
- U.S., Canada Begin ExCel Trial To Evaluate Aromasin For Breast Cancer Prevention
- Avastin Improves PFS In Advanced Breast Cancer
- Preoperative Drug Combo Benefits HER-2 Breast Cancer
- Combination Radiation/Vaccine May Benefit Some Patients
- “Inoperable” Prostate Cancer May Be Operable, Curable
- Benefit Seen In Novel Drug That Treats Gleevec Resistance
- NCI’s Rosenberg Confirms 2002 Immunotherapy Results
- NCI-Approved Clinical Trials
TCL
Vol.
31
No.
18
May 06, 2005
- NIH oncology peer reviewers are protesting the outcome of a recent meeting in which their own grant applications fared so poorly that the reviewers said they were penalized for their service.
- Also in this 8-page issue: FISH assay predicts survival on Iressa, Univ. of Colorado Cancer Center study finds.
- FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.
TCL
Vol.
31
No.
20
May 20, 2005
- ASCO President David Johnson to oncologists: It’s time to “reconnect to our patients” and “recommit to our profession.” Horning outlines priorities.
- Von Eschenbach says oncology is undergoing a “revolutionary evolution.”
- CCOPs ask NCI officials about one-year extensions.
- Varmus: Why are scientific societies obstructing public access to research results?
- Despite NCI director’s enthusiasm, “We have a long way to go before we beat cancer,” the former NIH director says.
- Onward to 2010? NCI promises faster progress for more money.
TCL
Vol.
31
No.
21
May 27, 2005
- Combined analysis moves Herceptin to adjuvant setting in breast cancer.
- Breast cancer session was ASCO equivalent of a rock concert, discussant says.
- Avastin doubles progression-free survival in metastatic disease.
- Also MQSA should require mammography facilities to gather data on interpretation, cancer policy board committee says.
- Colorado universities install huge NMR magnet. NCI to transfer 5 A Day to CDC.